{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lopez-Arencibia A"],"funding":["Consorcio Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Infecciosas, Ins-tituto de Salud Carlos III","Ministerio de Ciencia, España","Fundación CajaCanarias-Fundación Bancaria \"La Caixa\"","MePRAM Project, Instituto de Salud Carlos III, Funded by NextGenerationEU funds","Programa de Apoyos para la Superación del Personal Académico de la UNAM, Mexico","Cabildo de Tenerife"],"pagination":["13"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11766930"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["One of the most important steps in preclinical drug discovery is to demonstrate the in vivo efficacy of potential leishmanicidal compounds and good characteristics at the level of parasite killing prior to initiating human clinical trials. This paper describes the use of dehydrothyrsiferol (DT), isolated from the red alga <i>Laurencia viridis</i>, in a pharmaceutical form supported on Sepigel, and the in vivo efficacy against a mouse model of cutaneous leishmaniasis. Studying the ultrastructural effect of DT was also carried out to verify the suspected damage at the cellular level and determine the severity of damages produced in the homeostasis of promastigotes. BALB/c mice infected with <i>Leishmania amazonensis</i> were divided into four groups: untreated mice, mice treated with miltefo"],"journal":["Marine drugs"],"pubmed_title":["Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model."],"pmcid":["PMC11766930"],"funding_grant_id":["2022CLISA26","CB21/13/00100","CC20230222, CABILDO.23","PASPA 2021","PID2019-109476RB-C21","PMP22/00092"],"pubmed_authors":["Cen-Pacheco F","Lorenzo-Morales J","Omana-Molina M","Pinero JE","Diaz-Marrero AR","Rodriguez-Exposito RL","Lopez-Arencibia A","Fernandez JJ","San Nicolas-Hernandez D","Salazar-Villatoro L","Cordoba-Lanus E","Bethencourt-Estrella CJ","Dominguez-de-Barros A"],"additional_accession":[]},"is_claimable":false,"name":"Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model.","description":"One of the most important steps in preclinical drug discovery is to demonstrate the in vivo efficacy of potential leishmanicidal compounds and good characteristics at the level of parasite killing prior to initiating human clinical trials. This paper describes the use of dehydrothyrsiferol (DT), isolated from the red alga <i>Laurencia viridis</i>, in a pharmaceutical form supported on Sepigel, and the in vivo efficacy against a mouse model of cutaneous leishmaniasis. Studying the ultrastructural effect of DT was also carried out to verify the suspected damage at the cellular level and determine the severity of damages produced in the homeostasis of promastigotes. BALB/c mice infected with <i>Leishmania amazonensis</i> were divided into four groups: untreated mice, mice treated with miltefo","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-03T23:23:13.023Z","creation":"2025-04-03T23:23:13.023Z"},"accession":"S-EPMC11766930","cross_references":{"pubmed":["39852516"],"doi":["10.3390/md23010013"]}}